PT3388422T - Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral - Google Patents

Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral

Info

Publication number
PT3388422T
PT3388422T PT171665375T PT17166537T PT3388422T PT 3388422 T PT3388422 T PT 3388422T PT 171665375 T PT171665375 T PT 171665375T PT 17166537 T PT17166537 T PT 17166537T PT 3388422 T PT3388422 T PT 3388422T
Authority
PT
Portugal
Prior art keywords
receptor antagonist
solid dispersion
amorphous solid
hormone receptor
releasing hormone
Prior art date
Application number
PT171665375T
Other languages
English (en)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of PT3388422T publication Critical patent/PT3388422T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT171665375T 2017-04-13 2017-04-13 Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral PT3388422T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17166537.5A EP3388422B1 (en) 2017-04-13 2017-04-13 Amorphous solid dispersion of an orally available gonadotropin-releasing hormone receptor antagonist

Publications (1)

Publication Number Publication Date
PT3388422T true PT3388422T (pt) 2020-02-18

Family

ID=58547423

Family Applications (1)

Application Number Title Priority Date Filing Date
PT171665375T PT3388422T (pt) 2017-04-13 2017-04-13 Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral

Country Status (6)

Country Link
US (1) US10966979B2 (pt)
EP (1) EP3388422B1 (pt)
CA (1) CA3057950C (pt)
ES (1) ES2770132T3 (pt)
PT (1) PT3388422T (pt)
WO (1) WO2018189213A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
AU2018317472A1 (en) * 2017-08-18 2020-03-05 Abbvie Inc. Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
CN113912552A (zh) * 2020-07-09 2022-01-11 成都苑东生物制药股份有限公司 一种噁拉戈利钠无定型的制备方法
US11273128B1 (en) 2021-04-15 2022-03-15 Sandoz Ag Elagolix formulation
CN117545484A (zh) * 2021-04-21 2024-02-09 上海启晟合研医药科技有限公司 一种噁拉戈利钠组合物
EP4279075A1 (en) 2022-05-12 2023-11-22 Zaklady Farmaceutyczne Polpharma S.A. A pharmaceutical composition comprising elagolix

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000297A (es) 2003-07-07 2006-03-28 Neurocrine Biosciences Inc Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de gonadotropina.
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
US9949973B2 (en) 2015-07-07 2018-04-24 Abbvie Inc. Acoustic mixing for auto granulation
US20190321363A1 (en) * 2016-06-20 2019-10-24 Dr. Reddy's Laboratories Limited Process for the preparation of elagolix sodium and its polymorph

Also Published As

Publication number Publication date
CA3057950C (en) 2020-09-08
WO2018189213A1 (en) 2018-10-18
US20200022980A1 (en) 2020-01-23
EP3388422A1 (en) 2018-10-17
EP3388422B1 (en) 2019-11-20
US10966979B2 (en) 2021-04-06
CA3057950A1 (en) 2018-10-18
ES2770132T3 (es) 2020-06-30

Similar Documents

Publication Publication Date Title
PT3388422T (pt) Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral
EP3573602A4 (en) DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
EP3650449A4 (en) FXR RECEPTOR AGONIST
IL260307A (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
IL284005A (en) Glucocorticoid receptor inhibitors
EP3628005A4 (en) CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
SG11202001340VA (en) Quinoxaline derivatives as adenosine receptor antagonists
EP3594221A4 (en) GPR84 RECEPTOR ANTAGONISTS AND USES THEREOF
EP3666772A4 (en) DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST
SG11202009981RA (en) Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof
EP3703694A4 (en) MEDICINES ANTAGONISTS OF OPIOID RECEPTORS
IL271694A (en) Novel uses of a pure 6HT–5 receptor antagonist
HK1258023A1 (zh) 純5-ht6受體拮抗劑與nmda受體拮抗劑的組合
EP3350167A4 (en) Androgen receptor Antagonist
HUE055891T2 (hu) A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja
EP3406614A4 (en) OPIOID RECEPTOR ANTAGONIST CONJUGATE AND USE THEREOF
PT3774259T (pt) Dispositivo e método para preparação de microesferas expandidas
GB201816639D0 (en) GLP-1 Receptor Antagonist
HK1247105A1 (zh) Mu類鴉片受體拮抗劑與類鴉片藥劑的組合劑型
PT3620454T (pt) Derivado de ácido carboxílico como antagonista do recetor at2r
IL284081A (en) Somatostatin receptor antagonistic compounds and methods of using them
SG11202106401UA (en) Estrogen receptor antagonist
EP3165522A4 (en) Cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and use
EP3388423A4 (en) NK1 RECEPTOR ANTAGONIST
GB201700238D0 (en) Prodrugs of an angiotensin receptor agonist